Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 2/2016

01-02-2016 | Original Article – Clinical Oncology

Prostate cancer patients’ report on communication about endocrine therapy and its association with adherence

Authors: B. Jung, C. Stoll, G. Feick, F. J. Prott, J. Zell, I. Rudolph, J. Huebner

Published in: Journal of Cancer Research and Clinical Oncology | Issue 2/2016

Login to get access

Abstract

Background

Endocrine therapy is a mainstay of prostate cancer therapy. Given that few data exist on patient physician communication with regard to this field of therapy and adherence, we conducted a survey of patient members of a German support organization.

Patients and methods

We developed a structured questionnaire that was tested in a pilot version and then programmed as an online questionnaire.

Results

The questionnaire was completed by 694 patients. While 58 % of participants rated the information they received as comprehensive, 42 % did not. Fifty-one percentage stated that they were informed of side effects in detail, and 35 % received information on supportive treatments available in the event of side effects. Patients with higher education more often reported receiving information on side effects (p = 0.036) as well as alternatives for treatment (p = 0.001). Only 13 % stated that their questions were answered in detail, with 43 % receiving no answers or only non-detailed answers. Additional information was sought by 82 %, mostly from the Internet (67 %) and patient support groups (66 %). Seventy-six percentage experienced side effects that imposed limitations on their daily activities. Of those patients with side effects, 60 % reported that their physicians did not react to their complaints. There is a significant association between side effects in general and depression in particular and non-adherence (p < 0.01 and p = 0.002, respectively). In contrast, better information on side effects is associated with better adherence (p < 0001).

Conclusion

In order to improve adherence, detailed information on side effects and comprehensive supportive care is most important. Physicians should not rely on written information but should rather mainly engage in direct communication.
Literature
go back to reference Bell RJ, Fradkin P, Schwarz M, Davis SR (2013) Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis. Menopause 20(1):15–21PubMedCrossRef Bell RJ, Fradkin P, Schwarz M, Davis SR (2013) Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis. Menopause 20(1):15–21PubMedCrossRef
go back to reference Bourke L, Kirkbridge P, Hooper R, Rosario AJ, Chico TJA, Rosario DJ (2013) Endocrine therapy in prostate cancer: time fr reappraisal of risks, benefits and cost-effectiveness? Brit J Cancer 108(9):13 Bourke L, Kirkbridge P, Hooper R, Rosario AJ, Chico TJA, Rosario DJ (2013) Endocrine therapy in prostate cancer: time fr reappraisal of risks, benefits and cost-effectiveness? Brit J Cancer 108(9):13
go back to reference Cluze C, Rey D, Huiart L, BenDiane MK, Bouhnik AD, Berenger C, Carrieri MP, Giorgi R (2012) Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol 23:882–890PubMedCrossRef Cluze C, Rey D, Huiart L, BenDiane MK, Bouhnik AD, Berenger C, Carrieri MP, Giorgi R (2012) Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol 23:882–890PubMedCrossRef
go back to reference Gueth U, Myrick ME, Kilic N, Eppenberger-Castori S, Schmid SM (2012) Compliance and persistence of endocrine adjuvant breast cancer therapy. Breast Cancer Res Treat 131(2):491–499CrossRef Gueth U, Myrick ME, Kilic N, Eppenberger-Castori S, Schmid SM (2012) Compliance and persistence of endocrine adjuvant breast cancer therapy. Breast Cancer Res Treat 131(2):491–499CrossRef
go back to reference Harle LK, Maggio M, Shahani S, Braga-Basaria M, Basaria S (2006) Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Clin Adv Hematol Oncol 4(9):687–696PubMed Harle LK, Maggio M, Shahani S, Braga-Basaria M, Basaria S (2006) Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Clin Adv Hematol Oncol 4(9):687–696PubMed
go back to reference Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms; Langversion 3.1–2. Aktualisierung, Oktober 2014; AWMF-RegisterNummer 043/022OL Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms; Langversion 3.1–2. Aktualisierung, Oktober 2014; AWMF-RegisterNummer 043/022OL
go back to reference Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD (2006) Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 4:CD006019PubMed Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD (2006) Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 4:CD006019PubMed
go back to reference Liu Y, Malin JL, Diamant AL, Thind A, Maly RC (2013) Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Treat 137:829–836PubMedPubMedCentralCrossRef Liu Y, Malin JL, Diamant AL, Thind A, Maly RC (2013) Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Treat 137:829–836PubMedPubMedCentralCrossRef
go back to reference Mottet N, Peneau M, Mzeron JJ, Molinie V, Richaud P (2012) Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol 62(2):213–219PubMedCrossRef Mottet N, Peneau M, Mzeron JJ, Molinie V, Richaud P (2012) Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol 62(2):213–219PubMedCrossRef
go back to reference Nair B, Wilt T, MacDonald R, Rutks I (2002) Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 1:CD003506PubMed Nair B, Wilt T, MacDonald R, Rutks I (2002) Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 1:CD003506PubMed
go back to reference Payne H, Mason M (2011) Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments. Br J Cancer 105(11):1628–1634PubMedPubMedCentralCrossRef Payne H, Mason M (2011) Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments. Br J Cancer 105(11):1628–1634PubMedPubMedCentralCrossRef
go back to reference Steckelberg A, Berger B, Köpke S, Heesen C, Muehlhauser I (2005) Kriterien für evidenzbasierte Patienteninformationen. Z ärztl Fortb Qualitätssich 99:343–351 Steckelberg A, Berger B, Köpke S, Heesen C, Muehlhauser I (2005) Kriterien für evidenzbasierte Patienteninformationen. Z ärztl Fortb Qualitätssich 99:343–351
go back to reference Studer U, Whelan P, Albrecht W, Casselman J, Reijke TMD, Knoenageö H, Madersbacher S, Isorna S, Sundaram SK, Collette L (2011) Long term results of immediate versus deferred deprivation in patients with no local treatment for T0-4 N0-2 M0 prostate cancer (EORTC 30891). J Urol 185(4S):e144CrossRef Studer U, Whelan P, Albrecht W, Casselman J, Reijke TMD, Knoenageö H, Madersbacher S, Isorna S, Sundaram SK, Collette L (2011) Long term results of immediate versus deferred deprivation in patients with no local treatment for T0-4 N0-2 M0 prostate cancer (EORTC 30891). J Urol 185(4S):e144CrossRef
go back to reference Widmarl A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fossa SD (2009) Endocrine treatment with or without radiotherapy, in locally advances prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373(9660):301–308CrossRef Widmarl A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fossa SD (2009) Endocrine treatment with or without radiotherapy, in locally advances prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373(9660):301–308CrossRef
go back to reference Wuensch P, Hahne A, Haidinger R, Meißler K, Tenter B, Stoll C, Senf B, Huebner J (2015) Discontinuation and non-adherence to endocrine therapy in breast cancer patients: is lack of communication the decisive factor? J Cancer Res Clin Oncol 141(1):55–60PubMedCrossRef Wuensch P, Hahne A, Haidinger R, Meißler K, Tenter B, Stoll C, Senf B, Huebner J (2015) Discontinuation and non-adherence to endocrine therapy in breast cancer patients: is lack of communication the decisive factor? J Cancer Res Clin Oncol 141(1):55–60PubMedCrossRef
Metadata
Title
Prostate cancer patients’ report on communication about endocrine therapy and its association with adherence
Authors
B. Jung
C. Stoll
G. Feick
F. J. Prott
J. Zell
I. Rudolph
J. Huebner
Publication date
01-02-2016
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 2/2016
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-015-2059-2

Other articles of this Issue 2/2016

Journal of Cancer Research and Clinical Oncology 2/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.